84165-42-4Relevant academic research and scientific papers
Method for catalyzing nitrogen heterocyclic ring aerobic dehydrogenation based on ionic liquid porous carbon material
-
Paragraph 0048-0052, (2022/01/24)
The invention discloses a method for catalyzing nitrogen heterocycle aerobic dehydrogenation based on an ionic liquid porous carbon material, and is suitable for the field of organic synthesis. A heterogeneous catalysis system takes nitrogen heterocycle and derivatives thereof as substrates, a carbon material as a catalyst, water or ethanol as a solvent and air or oxygen spheres as an oxygen source, and a reaction is carried out at 0-80 DEG C under normal pressure, oxidative dehydrogenation of nitrogen heterocyclic compounds can be realized, and target products such as indole, quinoline, isoquinoline, quinazoline, quinoxaline, benzothiazole, Hanus ester and derivatives thereof and other medical intermediates can be synthesized. The non-metal catalyst is prepared by using the ionic liquid as the precursor, no activating agent or other additives are used in the reaction process, and the method has industrial application prospects.
A biomass-derived N-doped porous carbon catalyst for the aerobic dehydrogenation of nitrogen heterocycles
Cui, Fu-Jun,Guo, Fu-Hu,Liu, Jing-Jiang,Liu, Xiao-Yu,Quan, Zheng-Jun,Ullah, Arif,Wang, Xi-Cun,Zhu, Ji-Hua
supporting information, p. 1791 - 1799 (2022/01/31)
N-doped porous carbon (NC) was synthesized from sugar cane bagasse, which is a sustainable and widely available biomass waste. The preferred NC sample had a well-developed porous structure, a graphene-like surface morphology and different N species. More
Method for synthesizing aryl benzyl ether compound
-
Paragraph 0034; 0041, (2021/04/14)
The invention discloses a method for synthesizing aryl benzyl ether compounds, which comprises the following steps: by using an iron (III) complex containing 1, 3-di-tert-butyl imidazole cations and having a molecular formula of [(tBuNCH = CHNtBu) CH] [FeBr4] as a catalyst and di-tert-butyl peroxide as an oxidant, carrying out oxidative coupling reaction on phenolic compounds and toluene compounds to synthesize the corresponding aryl benzyl ether compounds. The method is the first example for preparing the aryl benzyl ether compound through the oxidative coupling reaction of the phenolic compound and the toluene compound, which is realized by an iron-based catalyst, and has the advantages of atom economy, environmental friendliness and good substrate applicability.
Application of iron (III) complex containing 1,3-di-tert-butyl imidazole cations in synthesis of aryl benzyl ether compounds
-
Paragraph 0033-0034, (2021/04/26)
The invention discloses an application of an iron (III) complex containing 1,3-di-tert-butyl imidazole cations in synthesis of aryl benzyl ether compounds, and particularly relates to a method for synthesizing corresponding aryl benzyl ether compounds by taking di-tert-butyl peroxide as an oxidizing agent and carrying out oxidative coupling reaction on phenolic compounds and toluene compounds. According to the method, the iron (III) complex is used as the catalyst for the first time, and oxidative coupling of the phenolic compound and the toluene compound is realized. The method is the first oxidative coupling reaction of phenolic compounds and benzyl C(sp3)-H bonds, and a new method is provided for synthesizing aryl benzyl ether compounds. Compared with an existing synthesis method, the method provided by the invention avoids using toxic and polluting halogenated hydrocarbon and strong base, has better atom economy, and conforms to the development concept of green synthetic chemistry.
COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH
-
Page/Page column 54, (2020/07/14)
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer.
Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines
Hu, Shuai,Jin, Yi,Liu, Yanghan,Ljungman, Mats,Neamati, Nouri
, p. 884 - 895 (2018/09/29)
Inhibition of proteasome activity blocks the degradation of dysfunctional proteins and induces cancer cell death due to cellular stress. Thus, proteasome inhibitors represent an attractive class of anticancer agents, and bortezomib, carfilzomib and ixazomib have been FDA-approved to treat multiple myeloma. However, cancer cells acquire resistance to these inhibitors through point mutations in the proteasome catalytic subunit or induction of alternative compensatory mechanisms. In this study, we identified a quinolin-chlorobenzothioate, QCBT7, as a new proteasome inhibitor showing cytotoxicity in a panel of cancer cell lines. QCBT7 is a more stable derivative of quinoline-8-thiol that targets the regulatory subunit instead of the catalytic subunit of the proteasome. QCBT7 caused the accumulation of ubiquitylated proteins in the cancer cells, indicating its proteasome inhibitory activity. Additionally, QCBT7 increased the expression of a set of genes (PFKFB4, CHOP, HMOX1 and SLC7A11) at both nascent RNA and protein levels, similarly to the known proteasome inhibitors MG132 and ixazomib. Together, QCBT7 induces proteasome inhibition, hypoxic response, endoplasmic reticulum stress and glycolysis, finally leading to cell death. Importantly, we have identified PFKFB4 as a potential biomarker of proteasome inhibitors that can be used to monitor treatment response.
Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase
Buchler, Ingrid,Akuma, Daniel,Au, Vinh,Carr, Gregory,De León, Pablo,Depasquale, Michael,Ernst, Glen,Huang, Yifang,Kimos, Martha,Kolobova, Anna,Poslusney, Michael,Wei, Huijun,Swinnen, Dominique,Montel, Florian,Moureau, Florence,Jigorel, Emilie,Schulze, Monika-Sarah E. D.,Wood, Martyn,Barrow, James C.
, p. 9647 - 9665 (2018/11/23)
A series of 8-hydroxy quinolines were identified as potent inhibitors of catechol O-methyltransferase (COMT) with selectivity for the membrane-bound form of the enzyme. Small substituents at the 7-position of the quinoline were found to increase metabolic stability without sacrificing potency. Compounds with good pharmacokinetics and brain penetration were identified and demonstrated in vivo modulation of dopamine metabolites in the brain. An X-ray cocrystal structure of compound 21 in the S-COMT active site shows chelation of the active site magnesium similar to catechol-based inhibitors. These compounds should prove useful for treatment of many neurological and psychiatric conditions associated with compromised cortical dopamine signaling.
ANTICANCER COMPOUNDS
-
Page/Page column 64; 65, (2018/11/22)
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.
Selectivity of N-versus O-alkylation in Mitsunobu reactions with various quinolinols and isoquinolinols
Hartung, Ryan E.,Wall, Mark C.,Lebreton, Sylvain,Smrcina, Martin,Patek, Marcel
, p. 1305 - 1313 (2017/07/18)
Reacting quinolinols and isoquinolinols under Mitsunobu conditions can give rise to N-alkylated products in addition to the normally desired O-alkylated structures. An in-depth study of how the solvent, reagent equivalents, position of the quinoline/isoqu
Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists
M?nnel, Barbara,Dengler, Daniela,Shonberg, Jeremy,Hübner, Harald,M?ller, Dorothee,Gmeiner, Peter
supporting information, p. 4693 - 4713 (2017/06/13)
By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (4), we designed and synthesized a collection of novel hydroxy-substituted heteroarylpiperazines and heteroarylhomopiperazines with high dopamine D2 receptor (D2R) affinity. In contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively mimicking those interactions of dopamine and the D2R that are crucial for an active state, leading to the recruitment of β-arrestin-2. Interestingly, some ligands show considerably lower intrinsic activity in guanine nucleotide exchange experiments at D2R and consequently represent biased agonists favoring β-arrestin-2 recruitment over canonical G protein activation. The ligands' agonistic properties are substantially driven by the presence of an endocyclic H-bond donor.
